View Item 

Show simple item record

Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer
dc.contributor.authorMcDaniel, Andrew S.
dc.contributor.authorFerraldeschi, Roberta
dc.contributor.authorKrupa, Rachel
dc.contributor.authorLanders, Mark
dc.contributor.authorGraf, Ryon
dc.contributor.authorLouw, Jessica
dc.contributor.authorJendrisak, Adam
dc.contributor.authorBales, Natalee
dc.contributor.authorMarrinucci, Dena
dc.contributor.authorZafeiriou, Zafeiris
dc.contributor.authorFlohr, Penelope
dc.contributor.authorSideris, Spyridon
dc.contributor.authorCrespo, Mateus
dc.contributor.authorFigueiredo, Ines
dc.contributor.authorMateo, Joaquin
dc.contributor.authorde Bono, Johann S.
dc.contributor.authorDittamore, Ryan
dc.contributor.authorTomlins, Scott A.
dc.contributor.authorAttard, Gerhardt
dc.date.accessioned2017-11-13T16:40:44Z
dc.date.available2019-01-07T18:34:39Zen
dc.date.issued2017-11
dc.identifier.citationMcDaniel, Andrew S.; Ferraldeschi, Roberta; Krupa, Rachel; Landers, Mark; Graf, Ryon; Louw, Jessica; Jendrisak, Adam; Bales, Natalee; Marrinucci, Dena; Zafeiriou, Zafeiris; Flohr, Penelope; Sideris, Spyridon; Crespo, Mateus; Figueiredo, Ines; Mateo, Joaquin; de Bono, Johann S.; Dittamore, Ryan; Tomlins, Scott A.; Attard, Gerhardt (2017). "Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer." BJU International 120(5B): E30-E44.
dc.identifier.issn1464-4096
dc.identifier.issn1464-410X
dc.identifier.urihttps://hdl.handle.net/2027.42/139087
dc.publisherSpringer New York
dc.publisherWiley Periodicals, Inc.
dc.subject.othercirculating tumour cells
dc.subject.otherliquid biopsy
dc.subject.othermetastatic castration‐resistant prostate cancer
dc.subject.otherERG
dc.subject.otherPTEN
dc.titlePhenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139087/1/bju13631_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139087/2/bju13631.pdf
dc.identifier.doi10.1111/bju.13631
dc.identifier.sourceBJU International
dc.identifier.citedreferencePantel K, Deneve E, Nocca D et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem 2012; 58: 936 – 40
dc.identifier.citedreferenceArmstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration‐resistant prostate cancer. Eur Urol 2012; 61: 549 – 59
dc.identifier.citedreferencede Cremoux P, Extra JM, Denis MG et al. Detection of MUC1‐expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real‐time polymerase chain reaction. Clin Cancer Res 2000; 6: 3117 – 22
dc.identifier.citedreferenceKrebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells‐biology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129 – 44
dc.identifier.citedreferenceHong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics 2013; 3: 377 – 94
dc.identifier.citedreferenceCristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781 – 91
dc.identifier.citedreferenceChen JF, Ho H, Lichterman J et al. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer 2015; 121: 3240 – 51
dc.identifier.citedreferenceArmstrong AJ, Marengo MS, Oltean S et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011; 9: 997 – 1007
dc.identifier.citedreferenceLarson CJ, Moreno JG, Pienta KJ et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62: 46 – 53
dc.identifier.citedreferenceStott SL, Lee RJ, Nagrath S et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2: 25ra3.
dc.identifier.citedreferenceAttard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration‐resistant prostate cancer. Cancer Res 2009; 69: 2912 – 8
dc.identifier.citedreferenceBeltran H, Rubin MA. New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res 2013; 19: 517 – 23
dc.identifier.citedreferenceBrenner JC, Chinnaiyan AM, Tomlins SA. ETS fusion genes in prostate cancer. In Tindall DJ ed, Prostate Cancer: Biochemistry, Molecular Biology and Genetics, Vol. Protein Reviews. New York: Springer New York, 2013: 139 – 83.
dc.identifier.citedreferenceGrasso CS, Wu YM, Robinson DR et al. The mutational landscape of lethal castration‐resistant prostate cancer. Nature 2012; 487: 239 – 43
dc.identifier.citedreferenceHsieh HB, Marrinucci D, Bethel K et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006; 21: 1893 – 9
dc.identifier.citedreferenceMarrinucci D, Bethel K, Bruce RH et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007; 38: 514 – 9
dc.identifier.citedreferenceMarrinucci D, Bethel K, Kolatkar A et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012; 9: 016003
dc.identifier.citedreferenceMarrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P. Circulating tumor cells from well‐differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch Pathol Lab Med 2009; 133: 1468 – 71
dc.identifier.citedreferenceWerner SL, Graf RP, Landers M et al. Analytical Validation and Capabilities of the Epic CTC Platform: enrichment‐Free Circulating Tumour Cell Detection and Characterization. J Circ Biomark 2015; 4: 3
dc.identifier.citedreferenceGundem G, Van Loo P, Kremeyer B et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015; 520: 353 – 7
dc.identifier.citedreferenceCrespo M, van Dalum G, Ferraldeschi R et al. Androgen receptor expression in circulating tumour cells from castration‐resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer 2015; 112 ( Suppl ): 1166 – 74
dc.identifier.citedreferenceCarreira S, Romanel A, Goodall J et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014; 6: 254ra125
dc.identifier.citedreferenceMiller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010; 2010: 617421
dc.identifier.citedreferenceReyal F, Valet F, de Cremoux P et al. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann Oncol 2011; 22: 1458 – 9
dc.identifier.citedreferenceOzkumur E, Shah AM, Ciciliano JC et al. Inertial focusing for tumor antigen‐dependent and ‐independent sorting of rare circulating tumor cells. Sci Transl Med 2013; 5: 179ra47.
dc.identifier.citedreferencePecot CV, Bischoff FZ, Mayer JA et al. A novel platform for detection of CK + and CK − CTCs. Cancer Discov 2011; 1: 580 – 6
dc.identifier.citedreferenceWatanabe M, Uehara Y, Yamashita N et al. Multicolor detection of rare tumor cells in blood using a novel flow cytometry‐based system. Cytometry A 2014; 85: 206 – 13
dc.identifier.citedreferenceGiordano A, Gao H, Anfossi S et al. Epithelial‐mesenchymal transition and stem cell markers in patients with HER2‐positive metastatic breast cancer. Mol Cancer Ther 2012; 11: 2526 – 34
dc.identifier.citedreferenceYu M, Bardia A, Wittner BS et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580 – 4.
dc.identifier.citedreferenceGorges TM, Tinhofer I, Drosch M et al. Circulating tumour cells escape from EpCAM‐based detection due to epithelial‐to‐mesenchymal transition. BMC Cancer 2012; 12: 178
dc.identifier.citedreferenceZhang L, Ridgway LD, Wetzel MD et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 2013; 5: 180ra48.
dc.identifier.citedreferenceKalluri R, Weinberg RA. The basics of epithelial‐mesenchymal transition. J Clin Invest 2009; 119: 1420 – 8
dc.identifier.citedreferenceScheel C, Weinberg RA. Cancer stem cells and epithelial‐mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012; 22: 396 – 403
dc.identifier.citedreferenceFerraldeschi R, Nava Rodrigues D, Riisnaes R et al. PTEN Protein Loss and Clinical Outcome from Castration‐resistant Prostate Cancer Treated with Abiraterone Acetate. Eur Urol 2015; 67: 795 – 802
dc.identifier.citedreferenceUdager AM, Shi Y, Tomlins SA et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer. Prostate 2014; 74: 1199 – 208
dc.identifier.citedreferenceMehra R, Tomlins SA, Yu J et al. Characterization of TMPRSS2‐ETS gene aberrations in androgen‐independent metastatic prostate cancer. Cancer Res 2008; 68: 3584 – 90
dc.identifier.citedreferenceLiu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559 – 65
dc.identifier.citedreferenceMiyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells‐monitoring treatment response in prostate cancer. Nat Rev Clin Oncol 2014; 11: 401 – 12
dc.identifier.citedreferenceDiamond E, Lee GY, Akhtar NH et al. Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012; 2: 131
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bju13631_am.pdf
Size:
1.572MB
Format:
PDF
View/Open
Name:
bju13631.pdf
Size:
1.131MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.